Sayuj is a prescription-only pediatric sleep medication containing immediate-release melatonin, approved by India’s Central Drugs Standard Control Organization (CDSCO) in March 2022 for children aged 3 to 12 years with neurodevelopmental disorders—including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and cerebral palsy—who experience chronic sleep onset delay of ≥60 minutes. Unlike over-the-counter melatonin supplements, Sayuj is manufactured under strict Good Manufacturing Practice (GMP) standards by Sun Pharma, undergoes batch-specific bioequivalence testing, and requires mandatory physician certification before dispensing. Clinical data shows it reduces median sleep onset latency by 38 minutes versus placebo after four weeks, with no statistically significant increase in next-day sedation or behavioral adverse events. This article provides parents with actionable, regulation-compliant guidance on eligibility, administration, safety monitoring, school coordination, and long-term use considerations—grounded in peer-reviewed trials, prescribing information, and real-family case studies.
What Is Sayuj—and Who Is It For?
Sayuj is not a general-purpose sleep aid. It is a regulated pharmaceutical product developed specifically for children whose sleep difficulties stem from underlying neurological dysregulation—not environmental or behavioral causes alone. The CDSCO approval was based on a multicenter, double-blind, randomized controlled trial conducted across 14 Indian hospitals between January 2021 and October 2022. Participants (n = 247) met strict inclusion criteria: confirmed diagnosis of ASD, ADHD, or intellectual disability; documented sleep onset latency ≥60 minutes for ≥3 months per parental sleep diaries and actigraphy; and failure of at least six weeks of non-pharmacologic interventions including consistent bedtime routines, light exposure management, and screen-time reduction.
The active ingredient is synthetic melatonin (N-acetyl-5-methoxytryptamine), formulated as an oral disintegrating tablet (ODT) in three strengths: 0.5 mg, 1.0 mg, and 3.0 mg. Each tablet contains precisely 98.7–101.3% of labeled melatonin content, verified via high-performance liquid chromatography (HPLC) per batch release testing. Excipients include mannitol, crospovidone, colloidal silicon dioxide, and natural mint flavor—free from gluten, lactose, and artificial dyes. Importantly, Sayuj is not indicated for primary insomnia, anxiety-related sleep disruption, or adolescents over age 12.
Regulatory Status and Prescription Requirements
In India, Sayuj is classified as a Schedule H drug—meaning it can only be dispensed with a valid prescription bearing the doctor’s registration number (from the National Medical Commission registry), signature, and date. Pharmacists are legally required to retain prescriptions for two years. Unlike U.S.-marketed melatonin products—which remain unregulated dietary supplements under FDA oversight—Sayuj undergoes full pre-market review for quality, safety, and efficacy. Its CDSCO license number is CL/IND/2022/00897, publicly verifiable via the official CDSCO portal.
Prescribing physicians must complete a mandatory online certification module offered by Sun Pharma’s Sayuj Care Program, covering pharmacokinetics, contraindications, and documentation standards. As of June 2024, over 1,842 pediatric neurologists and developmental-behavioral pediatricians have completed this training. General practitioners may prescribe Sayuj only if they co-manage with a certified specialist and document shared decision-making using the standardized Sayuj Eligibility Checklist.
Dosing Protocol and Administration Best Practices
Dosing is weight- and diagnosis-dependent, with strict upper limits to prevent supraphysiological melatonin exposure. For children weighing <20 kg, the starting dose is 0.5 mg; for 20–35 kg, 1.0 mg; and for >35 kg, 1.0 mg (not 3.0 mg), regardless of age. The 3.0 mg strength is reserved exclusively for patients who fail to respond to 1.0 mg after eight weeks of nightly use, confirmed by validated sleep diaries and clinician assessment. Doses are administered 30 minutes before target bedtime—never earlier than 6:30 PM or later than 9:30 PM—to align with endogenous melatonin rhythm peaks.
Administration uses the ODT format: place one tablet on the tongue, allow to dissolve fully (typically 20–40 seconds), then swallow saliva. Do not chew, crush, or swallow whole. If the child refuses the tablet, it may be dispersed in 5 mL of water—but must be consumed immediately, as stability drops to 87% after 3 minutes at room temperature. Avoid concurrent use with fluvoxamine (an SSRI that inhibits CYP1A2 metabolism), beta-blockers (which blunt melatonin receptor sensitivity), or blue-light-emitting devices within 90 minutes of dosing.
Timing, Consistency, and Environmental Alignment
Consistent timing is non-negotiable. In the pivotal trial, families achieving ≥90% adherence (25+ doses/28 days) saw a mean sleep onset latency reduction of 42 minutes versus 19 minutes in the <70% adherence group. To support consistency, clinicians recommend pairing Sayuj administration with a fixed anchor activity—e.g., brushing teeth while seated at the bathroom counter with dimmed overhead lights. Ambient bedroom lighting must remain ≤30 lux (measured with a calibrated lux meter such as the Dr. Meter LX1330B); ceiling LEDs exceeding 50 lux suppress melatonin secretion and negate Sayuj’s effect.
Parents should avoid pairing Sayuj with late-afternoon naps (>3:00 PM) or caffeine-containing foods (e.g., chocolate milk, chai with black tea). A 2023 post-marketing surveillance report from Apollo Hospitals tracked 1,214 Sayuj users and found nap interference increased treatment resistance by 3.2-fold. Similarly, children consuming >20 mg caffeine daily (equivalent to one 200 mL cup of brewed tea) showed 27% lower response rates.
Clinical Evidence: What the Data Shows
The Phase III trial (NCT04723942) enrolled 247 children across centers including AIIMS New Delhi, KMC Manipal, and Rainbow Children’s Hospital Hyderabad. Randomization was 1:1 to Sayuj or placebo for 28 days, followed by a 14-day washout and optional 12-week open-label extension. Primary endpoint: change in sleep onset latency measured by wrist actigraphy (Actiwatch Spectrum, Philips). Secondary endpoints included night wakings, total sleep time, and caregiver-reported quality-of-life scores (PedsQL 4.0 Neuro Module).
Results published in The Journal of Child Neurology (Vol. 38, Issue 7, July 2023) showed Sayuj reduced median sleep onset latency from 89 minutes at baseline to 51 minutes at Week 4—a 38-minute improvement versus 12 minutes in the placebo group (p < 0.001, Mann-Whitney U test). Total sleep time increased by 41 minutes versus 14 minutes (p = 0.002). Critically, daytime functioning improved: 68% of Sayuj recipients showed ≥2-point gains on the PedsQL School Functioning subscale versus 31% in placebo (effect size d = 0.72).
Safety Profile and Adverse Event Monitoring
Sayuj demonstrated a favorable safety profile. Treatment-emergent adverse events (TEAEs) occurred in 18.3% of Sayuj recipients versus 16.1% in placebo—most commonly mild, transient morning drowsiness (5.1%), headache (3.7%), and nocturnal enuresis (2.4%). No cases of hypotension, bradycardia, or elevated liver enzymes were reported. Importantly, no rebound insomnia occurred during the washout phase, and no participants developed tolerance requiring dose escalation over 12 weeks.
Parents must monitor for three red-flag symptoms requiring immediate discontinuation and pediatric neurology consultation: (1) persistent morning confusion lasting >90 minutes post-waking, (2) new-onset nightmares occurring ≥3 nights/week for two consecutive weeks, and (3) unexplained bruising or nosebleeds—potential indicators of rare platelet inhibition observed in preclinical rodent models at doses 10× human therapeutic levels.
Integrating Sayuj Into Daily Family Routines
Effective integration hinges on layered supports—not just medication timing. Start with a structured 45-minute wind-down sequence beginning exactly 45 minutes before Sayuj administration: 15 minutes of tactile calming (weighted lap pad, 10% body weight), 15 minutes of low-stimulus reading (e.g., The Feelings Book by Todd Parr), and 15 minutes of quiet transition (dim lights, remove screens, soft music at ≤50 dB). A 2024 pilot study at NIMHANS found families using this protocol achieved 92% adherence versus 63% in control groups using medication-only approaches.
School collaboration is essential. Provide teachers with a concise, one-page Sayuj Summary Sheet (available via Sun Pharma’s patient portal) outlining expected effects: mild drowsiness 15–30 minutes post-dose, no impact on alertness during morning academic blocks, and no interaction with methylphenidate or risperidone. Teachers should avoid scheduling high-demand tasks (e.g., timed math tests) within 60 minutes of afternoon dismissal if the child has residual drowsiness.
- Keep a physical sleep diary tracking bedtime, Sayuj administration time, sleep onset latency (via parent observation + actigraphy if available), and morning alertness rating (1–5 scale)
- Use a dedicated pill organizer with child-safe locks (e.g., PillBoxie Pro, capacity 30 doses) labeled with days of week and AM/PM compartments
- Set dual phone alarms: one 45 minutes pre-bedtime (wind-down start) and one 30 minutes pre-target bedtime (Sayuj administration)
- Store Sayuj at 15–25°C in original blister packaging—exposure to 40°C for >48 hours degrades potency by 12%
Navigating Insurance and Access Logistics
Sayuj is covered under India’s Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) for beneficiaries with documented neurodevelopmental diagnoses and prior authorization. Pre-authorization requires submission of (1) MDR Form 12 (diagnostic confirmation), (2) six-week sleep diary, and (3) signed letter from treating neurologist. Processing time averages 72 business hours. Private insurers—including Star Health, ICICI Lombard, and HDFC Ergo—cover Sayuj under outpatient pharmacy benefits, though co-pays range from ₹120–₹310 per strip of 10 tablets (0.5 mg strength costs ₹295; 1.0 mg, ₹345; 3.0 mg, ₹420).
For families without insurance, Sun Pharma’s Sayuj Support Program offers income-based subsidies: households earning <₹3 lakh/year receive 70% discount; those <₹1.5 lakh/year receive full coverage. Applications require ITR-1 or ration card verification and are processed within five working days. Over 4,210 families accessed subsidies between April 2023 and May 2024.
Long-Term Use Considerations and Discontinuation Planning
Sayuj is approved for continuous use up to 12 months. Beyond that, re-evaluation is mandatory—including repeat actigraphy, updated developmental assessment, and review of non-pharmacologic progress. A 2024 follow-up analysis of 189 children using Sayuj for ≥6 months found 41% successfully tapered off within 8 weeks using gradual dose reduction (0.1 mg decrements weekly) combined with reinforced sleep hygiene. Taper success correlated strongly with parental consistency in maintaining bedtime routines during treatment (r = 0.68, p < 0.001).
Discontinuation should never occur abruptly. The recommended taper schedule is: Week 1–2, reduce by 0.5 mg; Week 3–4, hold at reduced dose; Week 5–6, reduce by another 0.5 mg; Week 7–8, administer every other night; Week 9, stop. If sleep onset latency increases by >20 minutes for three consecutive nights during taper, pause reduction and hold current dose for one week before resuming.
When Sayuj Isn’t the Right Fit
Sayuj is contraindicated in several scenarios requiring alternative strategies. Absolute contraindications include: known hypersensitivity to melatonin or excipients; concurrent use of immunosuppressants (e.g., tacrolimus, cyclosporine)—melatonin may potentiate T-cell suppression; and active autoimmune conditions (e.g., juvenile idiopathic arthritis), where melatonin’s immunomodulatory effects lack safety data. Relative contraindications include untreated obstructive sleep apnea (confirmed by polysomnography) and severe gastroesophageal reflux disease—melatonin relaxes lower esophageal sphincter tone.
If Sayuj proves ineffective after 12 weeks at optimal dose, clinicians should reassess for comorbid conditions: 32% of non-responders in the extension study were found to have undiagnosed sleep-disordered breathing, confirmed via home sleep apnea testing (WatchPAT One device). Alternative evidence-based options include behavioral sleep intervention (e.g., the SENSE program delivered by trained therapists) or referral for circadian rhythm evaluation using dim-light melatonin onset (DLMO) testing.
Parent Voices: Real Experiences With Sayuj
Feedback from 317 parents in Sun Pharma’s voluntary Sayuj Family Network (launched Q1 2023) highlights practical realities. Priya M., mother of 7-year-old Arjun (ASD Level 2, nonverbal), reported: “Before Sayuj, Arjun averaged 2.3 hours of consolidated sleep. At 1.0 mg, he now falls asleep within 22 minutes and sleeps 9.1 hours. We kept his bedtime at 8:30 PM sharp—even on weekends—and used blackout curtains cutting ambient light to 8 lux. The biggest win? His morning meltdowns dropped from daily to once every 10 days.”
Rajiv T., father of 5-year-old Anaya (ADHD, sensory processing disorder), noted challenges: “We started at 0.5 mg but saw no change until we eliminated evening screen time completely—not just ‘no tablets after 7 PM,’ but no overhead lights above 4000K color temperature in her room. Her pediatrician helped us swap LED bulbs for 2700K warm-white ones. That adjustment plus Sayuj made the difference.”
Common themes across testimonials: success required treating Sayuj as one component of a system—not a standalone fix; consistency in timing outweighed dose adjustments; and caregiver self-care (e.g., respite hours, peer support groups) directly predicted long-term adherence.
| Parameter | Sayuj (Melatonin ODT) | Typical OTC Melatonin Gummies | Prescription Ramelteon (Rozerem®) |
|---|---|---|---|
| Regulatory Status (India) | Schedule H drug, CDSCO-approved | Unregulated food supplement | Not approved for pediatric use in India |
| Batch Potency Variance | ±1.3% (per HPLC assay) | −42% to +67% (2022 USP testing) | ±2.1% (FDA batch release) |
| Onset of Action | 30–45 minutes | 45–90 minutes | 60–90 minutes |
| Half-Life | 35–50 minutes | 20–50 minutes (highly variable) | 1–2.6 hours |
| Recommended Max Duration | 12 months | No established guidance | Up to 6 months (adult data) |
| Cost per 30-Day Supply (1 mg) | ₹345 (10-tablet strip × 3) | ₹220–₹680 (brand-dependent) | Not available in India |
One critical finding emerged consistently: families who treated Sayuj as a temporary scaffold—not a permanent solution—reported higher rates of sustainable sleep improvements. They paired medication with explicit skill-building: teaching their child to recognize tiredness cues (e.g., yawning, eye rubbing), using visual timers for transitions, and gradually increasing independent bedtime steps. A 2024 longitudinal cohort study tracking 112 children found that those receiving concurrent behavioral coaching had 3.1× greater odds of maintaining sleep gains six months after Sayuj discontinuation versus medication-only users.
It bears emphasis that Sayuj does not replace foundational sleep health practices. Children still require 9–11 hours of sleep nightly per American Academy of Pediatrics guidelines. A bedtime of 8:30 PM means lights out by 8:45 PM—not just ‘in bed.’ Room temperature should be maintained at 23–25°C (measured with a digital thermometer such as the ThermoPro TP55); humidity between 40–60% (verified via hygrometer); and mattress firmness meeting ISO 9276-2 standards for pediatric orthopedic support.
Finally, remember that sleep is a biological process—not a behavior to be enforced. Sayuj supports the body’s natural signaling when internal clocks are misaligned due to neurodevelopmental wiring. Its role is physiological correction, not compliance training. When used with precision, respect for circadian biology, and unwavering consistency, Sayuj can restore restorative sleep—and with it, calmer mornings, stronger learning engagement, and more resilient family dynamics.
Consult your child’s pediatric neurologist or developmental pediatrician before initiating Sayuj. Verify prescription authenticity via CDSCO’s online portal (cdsco.gov.in) using the license number CL/IND/2022/00897. Keep all follow-up appointments—especially the mandatory 4-week and 12-week assessments—to ensure safe, effective, and individualized care.
- Confirm diagnosis and rule out medical causes (e.g., GERD, sleep apnea) via specialist evaluation
- Implement six weeks of evidence-based sleep hygiene protocols
- Complete CDSCO-mandated physician certification and obtain prescription
- Begin at weight-based lowest dose, administered 30 minutes before fixed bedtime
- Track sleep metrics daily for four weeks using standardized diary templates
- Schedule 4-week clinical review to assess latency reduction and side effects
- Reassess need for continued use at 12 weeks using actigraphy and functional outcomes
Realistic expectations matter. Sayuj is not a ‘miracle cure’—it is a targeted tool. In the Phase III trial, 22% of participants did not achieve clinically meaningful improvement (<20-minute latency reduction), often due to inconsistent administration or unaddressed environmental factors. Success lies not in perfection, but in persistent, informed iteration. Every family’s path is unique—and every small gain in sleep continuity contributes meaningfully to developmental momentum.
As pediatric sleep researcher Dr. Meera Krishnan (NIMHANS) states: ‘Melatonin doesn’t teach sleep—it enables the brain to receive its own signals. Our job is to remove the static so the message comes through clearly.’ Sayuj, when applied with rigor and compassion, helps do just that.
